Episode 62: Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study

**Paper:** [Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study](https://doi.org/10.1186/s12916-023-03180-3) **Authors:** Wei-Jie Chen, Chun-Xia Gan, Yang-Wei Cai, Yang-Yang Liu, et al. **Journal:** BMC Medicine, 2023 **Why it matters:** Even when catheter ablation successfully restores heart rhythm, microscopic clots can silently lodge in the brain — and this trial tests whether a next-generation cooling catheter actually reduces that hidden risk. --- **Summary** Catheter ablation for atrial fibrillation (AF) — where radiofrequency energy is used to scar the tissue driving abnormal electrical signals — is highly effective, but the heat applied to actively circulating blood can generate micro-emboli (tiny clots and gaseous particles) that travel to the brain. These "silent cerebral embolisms" (SCEs) produce no immediate symptoms yet show up as new lesions on sensitive imaging in a substantial fraction of patients. This trial asked whether a high-power short-duration (HPSD) strategy, delivering 50 W through a Smart Touch Surround Flow (STSF) catheter — which features 56 circumferential irrigation holes designed to aggressively cool the electrode-tissue interface — reduces SCE incidence compared to the conventional 30–35 W approach using a standard Smart Touch (ST) catheter. One hundred AF patients were randomized 1:1. High-resolution diffusion-weighted MRI (1 mm slice thickness on a 3.0 T scanner) was performed before and 24–72 hours after ablation to detect new lesions, with cognitive function assessed by the Montreal Cognitive Assessment (MoCA) at baseline, immediately post-procedure, and at three months. The HPSD technique was procedurally faster and required less irrigation fluid, confirming it delivered on its engineering promise. However, SCE rates were nearly identical: 44% in the HPSD group versus 40% in the conventional group (p = 0.685), with no significant differences in lesion count, maximum diameter, or total lesion volume. Multivariable regression identified persistent AF and a high CHA₂DS₂-VASc score (a validated stroke-risk metric) as the only independent predictors of SCE — not the catheter type or ablation duration. The finding suggests that sluggish, turbulent blood flow in a structurally remodeled, dilated left atrium overwhelms any cooling advantage the hardware provides. Reassuringly, patients who developed SCEs showed no detectable cognitive decline at three months compared to those with clean scans. A key limitation is the relatively small sample of 100 patients, which may have been underpowered to detect modest differences. --- **Three takeaways** 1. The HPSD/STSF approach produced SCEs in 44% of patients versus 40% with conventional ablation — a difference that was not statistically significant (p = 0.685), meaning the advanced cooling catheter conferred no measurable brain protection. 2. Multivariable regression showed that persistent AF and CHA₂DS₂-VASc score — markers of adverse cardiac remodeling and baseline thrombotic risk — were the only independent predictors of SCE, with catheter type and ablation duration eliminated as predictors. 3. Despite 106 new lesions detected across 42 patients (92% in the telencephalon), MoCA scores were stable at both the immediate post-procedure and three-month assessments, suggesting micro-lesions of this scale do not translate to detectable short-term cognitive decline. --- **Read the paper:** [https://doi.org/10.1186/s12916-023-03180-3](https://doi.org/10.1186/s12916-023-03180-3)